365P - Is postmastectomy radiotherapy for patients diagnosed with breast cancer who have received neoadjuvant therapy really necessary?

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Surgical Oncology
Breast Cancer
Radiation Oncology
Presenter Rosa María Rodríguez
Authors R.M. Rodríguez1, M.T. Cano Osuna2, G. Pulido3, I. Porras1, P. Sánchez1, A. Moreno1, J. Jiménez1, M.J. Ortiz-Morales1, E. Aranda Aguilar4, J. De La Haba4
  • 1Medical Oncology, Universitay Hospital Reina Sofia, 14003 - Córdoba/ES
  • 2Oncologia Medica, Universitay Hospital Reina Sofia, Córdoba/ES
  • 3Medical Oncology, University Reina Sofia Hospital, Cordoba/ES
  • 4Oncology Deparment, IMIBIC-Hospital Reina Sofía, 14004 - Córdoba/ES



The role of adjuvant radiotherapy (RTA) after mastectomy in patients who have received neoadjuvant treatment is controversial and it has not been shown benefit in ramdomized clinical trials (ref ASCO-Guide lines). On the other hand, the low rates of local and distant recurrences after complete pathological response (RPc) question the value of local control disease.


To analyze the rate and profile of recurrence in breast cancer patients who have received neoadjuvant chemotherapy, mastectomy with and without radiotherapy.

Patients and methods

From the Department of Medical Oncology, University Hospital Reina Sofia we have identified 171 patients between 1997 and 2010 who have received neoadjuvant treatment. 36 patients have not received radiotherapy treatment after mastectomy. We present clinical and biological features of patients and their evolution.


The mean age is 53 years, 100% are stage II and III (55.6% and 44.4%), infiltrating ductal histology (88.9%) and poorly differentiated tumors (44.4%). Regarding to hormonal status, 58.3% are hormone receptor positive and Her-2 33.3% and 21% are triple negative. The rate of pathological complete response (T and N) is 22.2%. at T of 41.7%.

With a follow-up mean of 19.92 months (SD: 13.9), we have found one recurrence of the disease localized in liver. At this moment we do not have any local recurrence.


Based on our experience and the lack of data supporting radiotherapy in these patients, we believe that radiotherapy should be assessed on individual basis, pending randomized studies provide direct benefit.


All authors have declared no conflicts of interest.